Thus, we hypothesize that celecoxib may effectively delay the progression of hepatic steatosis to advanced liver diseases in individuals with hepatic metabolic alterations induced by the insulin‐driven activation of PI3K/AKT/mTORC1 signalling in hepatocytes. The gene discussed is INS; the disease is Hepatic steatosis.